3.1. Secondary Endpoints
toxicity, diarrhea
PERIPHERAL NEUROPATHY
The rates of toxicity for the two study arms are summarized in Eight patients in each arm had a dose reduction (33.3% TC-H versus 34.8% P-H arms). However, only one patient (4.2%) on TC-H prematurely discontinued chemotherapy compared with 7 (30.4%) patients on P-H. While the most common reason for dose reduction was diarrhea (2 patients in each arm), peripheral neuropathy led to chemotherapy discontinuation in 20% of the patients in the TC-H arm. Two patients on the P-H arm had a change in their chemotherapy regimen—one patient switched to abraxane due to a reaction to paclitaxel, and another patient added carboplatin.